Select Page

AI-driven adverse events monitoring

Leverage process excellence for data capture and transmission, expertise in signal detection with advanced analytics, and data harmonization using standards.


Transform pharmacovigilance by leveraging data and advanced analytics


To ensure patient safety and mitigate the risks associated with adverse events (AEs), life sciences companies are proactively monitoring and assessing the benefit-risk profile of a medicinal product early in the product’s life cycle. Modern advanced analytics techniques are raising the bar even further. By examining large and varied data sets containing safety information, companies can uncover hidden patterns, trends, and patient preferences and gain insights to comply with AEs reporting requirements and also predict and prevent them. Through AI-enabled analytics, companies are transitioning from mere reporting and monitoring (what happened and what is happening now) to evaluation, prediction, and prescription (why did it happen, what will happen next, what to do to prevent it).

Leverage our expertise in the regulatory submission process, AE reconciliation, and enhanced safety monitoring and corrective actions to increase the success rate of your clinical trials!

Read Blog / The innovative path forward in clinical trials

Events monitoring

AE case management

Expedited and aggregated reporting

Signal intelligence

Service offering

Key results

Business outcomes

Process excellence for data capture and transmission

Signal detection with advanced analytics

Data harmonization using standards

Group 47548

Signal detection proof of concept

Group 47658

Roadmap to apply automation

Group 47581

Steps to adopt data standards

Clinical program access

  • Design clinical trials with an emphasis on patients with critical diagnosis even before early access programs (EAPs) and in line with managed access programs.

Agile clinical development

  • Enroll faster, retain patients longer, and reach a more representative patient population.